Investor Presentation First Nine Months of 2023
Therapy
areas
30
Investor presentation
First nine months of 2023
Core capabilities and additional technology platforms open up
new opportunities across therapy areas
Diabetes care
Obesity care
CVD
MASH
RBD
RED
Other areas
ao
Co
m
Technology platforms
O
Proteins / Peptides Oligonucleotides / RNAi Stem cells Genome editing / Gene therapy
110
20
Currently active
20
110
OD
11
114
CO
114
Note: Currently active means Novo Nordisk is currently pursuing research projects, while exploratory potential indicates that the platform is potentially applicable for the given disease
RBD: Rare blood disorders; RED: Rare endocrine disorders; CVD: Cardiovascular disease; MASH: Metabolic dysfunction-associated steatohepatitis; RNA: Ribonucleic acid
Exploratory potential
10
O
O
O
50
10
101
16
110
91
12
Injectable administration
B
Oral administration
Novo NordiskⓇView entire presentation